Multiple target antigen stimulating cell therapy - HengRui YuanZheng Biotechnology
Latest Information Update: 06 Sep 2016
At a glance
- Originator HengRui YuanZheng Bio-Technology
- Class Cell therapies; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Solid tumours
Most Recent Events
- 06 Sep 2016 Clinical trials in Solid tumours in China (IV) before September 2016
- 06 Sep 2016 HengRui YuanZheng Bio-Technology plans a phase I/II trial for Solid tumours in China (NCT02858232)